Skip to content
Companies

Neosoma

AI brain MRI tumor mapping for neuro-oncology teams

Raised to date

$3.5M

of $5.8M offered across 1 Form D filing

Still open
$2.3M
Investors
52
Last filed
Mar 27, 2026

About

Neosoma is a medical technology company in Groton, Massachusetts that builds AI software for neuro-oncology imaging. Its cloud platform analyzes brain MRI scans to segment tumors at voxel-level precision, compute volumetric tumor burden, generate contours for radiation treatment planning, and track lesions longitudinally across timepoints. The company holds FDA 510(k) clearances for Neosoma HGG (high-grade glioma, cleared 2022) and Neosoma Brain Mets (brain metastases, cleared December 2025). The platform is SOC 2 Type II certified and HIPAA compliant, and is used at clinical sites including UCLA, UF Health, JFK Hackensack and Methodist Health System.

FDA-cleared, fully automated 3D tumor segmentation and longitudinal tracking for brain cancer, replacing manual radiologist measurement and feeding contours directly into radiation treatment planning systems, with Category 3 CPT codes available for reimbursement.

Funding

  • EquityFiled Mar 27, 2026Form D
    $3.5M/ $5.8M

Product

Neosoma cloud platform

Clinical AI imaging software

A cloud-based, FDA-cleared AI platform that ingests brain MRI studies and automatically maps, contours, quantifies and tracks tumor lesions for multidisciplinary neuro-oncology teams.

  • Voxel-level segmentation of intratumoral lesion compartments
  • GTV contour generation exportable to radiation treatment planning software
  • Automatic tumor burden and lesion count calculation across timepoints

Built for

Hospitals and cancer centers with neuro-oncology programs, specifically neurosurgeons, radiation oncologists and neuro-oncology multidisciplinary tumor boards

People on file